Artemisinin drug resistance is one of the major reasons for malaria treatment failures in the sub-Saharan African
countries where artemisinin-based combination therapy (ACT) is the first-line treatment for uncomplicated malaria.
The occurrence of single nucleotide polymorphisms (SNPs) is found to correla...
Artemisinin drug resistance is one of the major reasons for malaria treatment failures in the sub-Saharan African countries where artemisinin-based combination therapy (ACT) is the first-line treatment for uncomplicated malaria.
The occurrence of single nucleotide polymorphisms (SNPs) is found to correl...
With roughly 50 % of the global population at risk for infection, malaria is one of the most serious public health problems in the world. This infection is caused by single-celled protozoa of the genus Plasmodium. By the turn of the century, the majority of antimalarial drugs were no longer effective aga...
Background: The entire population of Mozambique is at risk for malaria, which remains one of the leading causes of death. The 2017-2022 National Malaria Strategic Plan focuses on reducing malaria morbidity and mortality in high- and low-transmission areas. This study aimed to estimate the costs and healt...
Background: Nigeria adopted the Artemisinin-Based Combination Therapy (ACT) as the mainstay of treating uncomplicated malaria in February 2005. However, the individual preferences for the use of these medicines by health care professionals (HCP) as distinct from their observed prescribing practices is la...
Objective:The antimalarial preferences, tolerability, and cost of the Artemisinin-based combination therapies (ACTs) among adult patients and caregivers are largely understudied despite being the recommendedtreatment for Plasmodium falciparum.We, therefore, evaluated antimalarial preferences, t...
Background: Due to the threat of emerging anti-malarial resistance, the World Health Organization recommends incorporating surveillance for molecular markers of anti-malarial resistance into routine therapeutic efficacy studies (TESs). In 2018, a TES of artemether-lumefantrine (AL) and artesunate-amodiaq...
Antimalarials/pharmacology,
Antimalarials/therapeutic use,
Artemisinins/pharmacology,
Artemisinins/therapeutic use,
Drug Resistance/genetics,
Drug Therapy, Combination,
Genetic Markers,
Plasmodium falciparum/radiation effects,
Plasmodium falciparum/genetics,
Plasmodium falciparum/isolation & purification,
Polymorphism, Genetic/genetics,
Mozambique
Orvalho, Augusto;
Stergachis, Andy;
Dellicour, Stephanie;
Tinto, Halidou;
Valá, Anifa;
Ruperez, Maria;
Macete, Eusébio;
Nakanabo-Diallo, Seydou;
Kazienga, Adama;
Valéa, Innocent;
d'Alessandro, Umberto;
Kuile, Feiko O Ter;
S Calip, Gregory;
Ouma, peter;
Desai, Meghna;
Sevene, Esperança.
While there is increasing evidence on the safety of artemisinin-based combination therapy (ACT) for the case management of malaria in early pregnancy, little is known about the association between exposure to ACT during the first trimester and the effect on fetal growth. Data were analysed from prospecti...
Combined Modality Therapy,
Artemisinins,
Antimalarials,
Malaria,
Pregnancy,
Pregnancy Trimester, First,
Infant, Small for Gestational Age,
Infant, Low Birth Weight
Sevene, esperança;
Banda, clifford G;
Mukaka, mavuto;
Maculuve, sonia;
Vala, anifa;
Macuacua, salésio;
Piqueras, mireia;
Phiri, linda kalilani;
Mallewa, jane;
Terlouw, dianne J;
Khoo, saye H;
Lalloo, david G;
Mwapasa, victor.
Background: HIV-infected individuals on antiretroviral therapy (ART) require treatment with artemisinin-based combination therapy (ACT) when infected with malaria. Dihydroartemisinin–piperaquine (DPQ) is recommended for treatment of Plasmodium falciparum malaria, but its efcacy and safety has not been ...
Adjei, aexander;
Bana, solomon narh;
Amu, alberta;
Kukula, vida;
Nagai, richard afedi;
Agyei, seth owusu;
Oduro, abraham;
Macete, Eusebio;
Abdulla, salim;
Halidou, tinto;
Sie, ali;
Osei, isaac;
Sevene, esperance;
Asante, kwaku-poku;
Mulokozi, abdunoor;
Compaore, guillaume;
Valea, innocent;
Adjuik, martin;
Baiden, rita;
Ogutu, Bernhards;
Binka, fred;
Gyapong, margaret.
Background: Dihydroartemisinin-piperaquine (DHA-PQ) is one of five WHO recommended artemisinin combination therapy (ACT) for the treatment of uncomplicated malaria. However, little was known on its post-registration safety and effectiveness in sub-Saharan Africa. DHA-PQ provides a long post-treatment pro...
